Robert M. Wenham, MD

Robert Wenham, MD, MS, FACOG, FACS, discusses the importance of clinical trials in ovarian cancer.

Robert Wenham, MD, MS, FACOG, FACS, discusses the role of antibody-drug conjugates in ovarian cancer.

Robert Wenham, MD, MS, FACOG, FACS, discusses the potential for immunotherapy in ovarian cancer.

Robert Wenham, MD, MS, FACOG, FACS, discusses future directions with antibody-drug conjugates in the treatment of patients with ovarian cancer.

Robert Wenham, MD, MS, FACOG, FACS, discusses novel immunotherapy combinations for the treatment of patients with ovarian cancer.

Robert M. Wenham, MD, gynecologic oncologist and chair of the Gynecologic Oncology Program at Moffitt Cancer Center, discusses data with intraperitoneal (IP) chemotherapy, dose-dense chemotherapy, and intravenous (IV) chemotherapy in patients with advanced ovarian cancer.

Robert M. Wenham, MD, gynecologic oncologist and chair of the Department of Gynecologic Oncology at Moffitt Cancer Center, sheds light on the debate between neoadjuvant chemotherapy and primary debulking surgery in patients with newly diagnosed, advanced ovarian cancer.